Kairos Pharma (NYSEAMERICAN:KAPA) Receives Buy Rating from D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Kairos Pharma Stock Performance

Shares of NYSEAMERICAN:KAPA opened at $1.21 on Wednesday. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.